189 related articles for article (PubMed ID: 36567628)
1. ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.
Qian Y; Zhang X; Mao S; Wei W; Lin X; Ling Q; Ye W; Li F; Pan J; Zhou Y; Zhao Y; Huang X; Huang J; Tong H; Sun J; Jin J
Mol Oncol; 2023 Jul; 17(7):1402-1418. PubMed ID: 36567628
[TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY
Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062
[TBL] [Abstract][Full Text] [Related]
4. The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
Li X; Yin X; Wang H; Huang J; Yu M; Ma Z; Li C; Zhou Y; Yan X; Huang S; Jin J
Oncotarget; 2017 Feb; 8(8):12764-12774. PubMed ID: 28061447
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
6. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
7. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
8. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
9. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
10. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
11. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
13. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
15. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
[TBL] [Abstract][Full Text] [Related]
16. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
17. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia.
Wu Z; Zhuang H; Yu Q; Zhang X; Jiang X; Lu X; Xu Y; Yang L; Wu B; Ma A; Zhang L; Xiao X; Liang Y; Gao R; Shen J; Xu R
Transl Oncol; 2019 Jun; 12(6):801-809. PubMed ID: 30953928
[TBL] [Abstract][Full Text] [Related]
19. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
20. Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines.
Zhang S; Liu J; Lu ZY; Xue YT; Mu XR; Liu Y; Cao J; Li ZY; Li F; Xu KL; Wu QY
Cell Oncol (Dordr); 2022 Oct; 45(5):1005-1018. PubMed ID: 36036884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
